| Authors: |
van Dorp J; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands., Pipinikas C; Inivata Ltd., Babraham Research Park, Cambridge, UK., Suelmann BBM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Mehra N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., van Dijk N; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Marsico G; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Montfoort ML; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hackinger S; Inivata Ltd., Babraham Research Park, Cambridge, UK., Braaf LM; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands., Amarante T; Inivata Ltd., Babraham Research Park, Cambridge, UK., van Steenis C; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, The Netherlands., McLay K; Inivata Ltd., Babraham Research Park, Cambridge, UK., Daletzakis A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Meijer RP; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urological Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., van der Heijden AG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Rosenfeld N; Inivata Ltd., Babraham Research Park, Cambridge, UK.; Cancer Research UK Cambridge Institute, Cambridge, UK.; Cancer Research UK Major Centre Cambridge, Cancer Research UK Cambridge Institute, Cambridge, UK., van Rhijn BWG; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands.; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany., Jones G; Inivata Ltd., Babraham Research Park, Cambridge, UK. greg.jones@inivata.com., van der Heijden MS; Dutch Uro-Oncology Study Group, Bilthoven, The Netherlands. ms.vd.heijden@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl. |
